DrugBiological
CM336 clinical trials
- studies test it
- 12
- open now
- 12
- in phase 3
- 1
- first study started
- 2024
Keep track of what changes. Save the CM336 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 8
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 8
Institute of Hematology & Blood Diseases Hospital, China (7) · Keymed Biosciences Co.Ltd (4) · Shandong First Medical University (1)
Often tested with
Tested in the same studies.
Lenalidomide (2) · Daratumumab (1) · Sonrotoclax (1) · Isatuximab (1) · Bortezomib (1)
Studies
Open first, then newest update. How each study uses CM336 is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Evaluate CM336 in Adults With Autoimmune Bullous DiseaseRecruitingPhase 2Shandong First Medical UniversityNCT06900010Written as CM336 Injection
- BCMA/CD3 BsAb Therapy for POEMS SyndromeRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07115654Written as CM336 (BCMA/CD3 bispecific antibody)
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as CM336 (BCMA/CD3 bispecific antibody)
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07652905Written as CM336
- BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple MyelomaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06745687Written as CM336
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07687004Written as CM336 (BCMA/CD3 bispecific antibody)
- CM336 for Active Sjogren's Syndrome StudyNot yet recruitingPhase 1Keymed Biosciences Co.LtdNCT07642843Written as CM336
- BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMMNot yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07407010Written as CM336 (BCMA/CD3 bispecific antibody)
- A Study of CM336 in Patients With Relapsed or Refractory Autoimmune CytopeniaRecruitingPhase 1/2Keymed Biosciences Co.LtdNCT07175493Written as CM336 Injection
- Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain AmyloidosisRecruitingPhase 2Keymed Biosciences Co.LtdNCT07039578Written as CM336 Injection(Low dose group)
- Study of CM336 in Relapsed or Refractory Multiple Myeloma PatientsNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT07181239Written as CM336 Injection
- An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune ThrombocytopeniaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06799611Written as CM336 Injection